FIGURE 1.

Effect of covariates on lecanemab AUC and C _max at steady state after 10 mg/kg bi‐weekly. Covariate effects are expressed as lecanemab exposures at steady state relative to a reference subject (72 kg male, non‐Japanese subject with albumin of 43 g/L who was administered Process A drug product with all PK samples ADA negative). Body weight and albumin test categories (49 and 99 kg for body weight, 39 and 48 g/L for albumin) represent the 5th and 95th percentiles of PK analysis set, respectively. Gray area indicates the acceptance interval (0.80–1.25). AUC, area under the curve; CI, confidence interval; C _max, maximum concentration; PK, pharmacokinetic.